Branded drug prices fell in the US in 2025. First time in decades.
Not because PBMs negotiated harder. Because manufacturers built direct cash channels around them. Lilly Direct on Zepbound. NovoCare Pharmacy Direct on Wegovy at $499/mo flat. PfizerForAll. BMS-Pfizer on Eliquis. Harrow on VEVYE at $59 through AccessForAll.
When a commercially-insured patient opts out into a manufacturer cash channel, the PBM loses more per script than the manufacturer does. Every branded manufacturer with credible cash demand now has a real BATNA against rebate compression.
PBMs see it. Cigna announced "rebate-free" commercial PBM for 2027. Optum Rx and CVS Caremark followed with cost-plus reimbursement models. Not customer-experience improvements. The PBM oligopoly conceding the rebate-spread model before being forced off it.
Government is on the same side. TrumpRX is being built as a state-backed manufacturer-direct platform. The Cigna FTC insulin settlement requires Cigna to count TrumpRX purchases toward patient deductibles.
The endgame falls out from first principles. The PBM model has three legs: rebate negotiation, formulary control, adjudication. Manufacturer-direct erodes leg one. Cash-pay erodes leg two. Only adjudication is hard to replicate.
PBMs end up as utilities. Adjudication and claims for the chronic and generic book at utility margins. Branded specialty, GLP-1, and lifestyle bifurcates to manufacturer-direct. Cigna's 2027 commercial roll-out is the timeline. A 2026-2028 inflection, not a five-year story.
Compressed: CVS Health, UnitedHealth, Cigna in the pharmacy benefit segment. Conglomerate cover masks it at the parent level. Beneficiaries: manufacturers with credible cash channels live today, and the DTC enablement layer. The swing variable is refill persistence on the new direct channels.